BIOMAT Database Logo BIOMAT Database Logo

Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma. 1995

P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
Biochemistry Department, Boston University School of Medicine, MA 02118, USA.

OBJECTIVE To measure the urinary excretion of specific cross-link amino acid markers for mature elastin (desmosine [DES] and isodesmosine [IDES]) and fibrillar collagen (hydroxylysylpyridinoline [HP] and lysylpyridinoline [LP]) in systemic sclerosis (SSc) patients and healthy controls. METHODS Urine specimens from 20 patients with SSc and 22 controls were assessed for DES, IDES, HP, and LP using high performance liquid chromatography and ultraviolet absorption spectroscopy, in combination with an isotope dilution technique in which the urine specimen was spiked with isotopically labeled cross-link amino acids. RESULTS Mean +/- SD levels of urinary DES and IDES were elevated in SSc patients by 2-3-fold, and urinary HP and LP by 3-4-fold, compared with controls (DES 21.0 +/- 9.4 versus 7.5 +/- 1.4 micrograms/gm creatinine; HP 109.0 +/- 72.9 versus 24.9 +/- 5.7 nmoles/mmole creatinine). Nineteen of the 20 SSc patients had urinary DES and HP values that were > 3 SD above the control mean. A significant elevation in the HP:LP ratio in SSc patients as compared with controls (mean +/- SD 6.9 +/- 1.5 versus 5.5 +/- 1.3) indicated a soft tissue origin for much of the increased HP. CONCLUSIONS Patients with SSc have higher levels of urinary cross-link amino acids specific for the degradation of mature collagen and elastin. These markers distinguish most SSc patients from healthy controls.

UI MeSH Term Description Entries
D007524 Isodesmosine 2-(4-Amino-4-carboxybutyl)-1-(5-amino-5-carboxypentyl)-3,5-bis(3-amino-3-carboxypropyl)pyridinium. A rare amino acid found in elastin, formed by condensation of four molecules of lysine into a pyridinium ring.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D003895 Desmosine A rare amino acid found in elastin, formed by condensation of four molecules of lysine into a pyridinium ring. 4-(4-Amino-4-Carboxybutyl)-1-(5-Amino-5-Carboxypentyl)-3,5-bis(3-Amino-3-Carboxypropyl)pyridinium
D004549 Elastin alpha-Elastin,kappa-Elastin,alpha Elastin,kappa Elastin
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
Elastin and collagen degradation products in urine of patients with cystic fibrosis.
July 1995, American journal of respiratory and critical care medicine,
P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease.
April 1995, American journal of respiratory and critical care medicine,
P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
Collagen and elastin in scleroderma.
January 1974, Connective tissue research,
P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
Collagen/elastin hydrogels cross-linked by squaric acid.
March 2016, Materials science & engineering. C, Materials for biological applications,
P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
[Collagen metabolites in the urine in patients with generalized scleroderma].
May 1984, Ugeskrift for laeger,
P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma.
January 2007, Folia biologica,
P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
[Cross-linked fibrin degradation products (XDP)].
September 1999, Nihon rinsho. Japanese journal of clinical medicine,
P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
[Pyridinoline-containing collagen degradation products in urine in coxarthrosis].
January 1991, Zeitschrift fur Rheumatologie,
P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
Determination of collagen degradation products in human urine in osteoarthrosis.
January 1987, Zeitschrift fur Rheumatologie,
P J Stone, and J H Korn, and H North, and E V Lally, and L C Miller, and L B Tucker, and S Strongwater, and G L Snider, and C Franzblau
Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma?
December 1998, The British journal of dermatology,
Copied contents to your clipboard!